Disease · MONDO_0024331
Comparisons in its trials35
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 35
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| FOLFIRI + Ramucirumab vs FOLFIRI + Placebo: serious adverse events | 198 of 529 | 175 of 528 | 1,057 | NCT01183780 | Trial comparisons |
| Xilonix vs Placebo: deaths from any cause | 28 of 411 | 13 of 200 | 611 | NCT01767857 | Trial comparisons |
| Xilonix vs Placebo: serious adverse events | 169 of 411 | 84 of 200 | 611 | NCT01767857 | Trial comparisons |
Part 2 Dose Expansion: NKTR-214 (0.006 mg/kg) q3w + Nivolumab (360 mg) q3w vs Part 4 Dose Expansion of NKTR-214 + Nivolumab + Ipilimumab: Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D) | 64 of 429 | 3 of 17 | 446 | NCT02983045 | Trial comparisons |
| Pembrolizumab vs Standard of Care (SOC): Number of Participants Who Discontinued Study Treatment Due to an AE | 21 of 153 | 20 of 143 | 296 | NCT02563002 | Trial comparisons |
| Pembrolizumab vs Standard of Care (SOC): Number of Participants Who Experienced an Adverse Event (AE) | 149 of 153 | 142 of 143 | 296 | NCT02563002 | Trial comparisons |
| BBI608 vs Placebo: Disease Control Rate | 17 of 138 | 18 of 144 | 282 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: Number of Patients With Adverse Events | 135 of 136 | 139 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: deaths from any cause | 127 of 136 | 130 of 144 | 280 | NCT01830621 | Trial comparisons |
| BBI608 vs Placebo: serious adverse events | 40 of 136 | 29 of 144 | 280 | NCT01830621 | Trial comparisons |
| Cohort A - Pembrolizumab 200 mg vs Cohort B - Pembrolizumab 200 mg: Number of Participants Who Experienced an Adverse Event (AE). | 60 of 61 | 63 of 63 | 124 | NCT02460198 | Trial comparisons |
| Cohort A - Pembrolizumab 200 mg vs Cohort B - Pembrolizumab 200 mg: Number of Participants Who Discontinued Study Treatment Due to an AE. | 5 of 61 | 5 of 63 | 124 | NCT02460198 | Trial comparisons |
| Part 1 Panitumumab + Irinotecan vs Part 2 Panitumumab + AMG479: deaths from any cause | 66 of 74 | 30 of 36 | 110 | NCT00891930 | Trial comparisons |
| Part 1 Panitumumab + Irinotecan vs Part 2 Panitumumab + AMG479: serious adverse events | 26 of 74 | 8 of 36 | 110 | NCT00891930 | Trial comparisons |
| Group A vs Group B: deaths from any cause | 2 of 56 | 0 of 54 | 110 | NCT02337946 | Trial comparisons |
| Group A vs Group B: serious adverse events | 20 of 56 | 18 of 54 | 110 | NCT02337946 | Trial comparisons |
| Ompenaclid + FOLFIRI + Bevacizumab vs Placebo + FOLFIRI + Bevacizumab: Disease Control Rate (DCR) | 36 of 38 | 30 of 38 | 76 | NCT05983367 | Trial comparisons |
| Ompenaclid + FOLFIRI + Bevacizumab vs Placebo + FOLFIRI + Bevacizumab: deaths from any cause | 4 of 38 | 11 of 38 | 76 | NCT05983367 | Trial comparisons |
| Ompenaclid + FOLFIRI + Bevacizumab vs Placebo + FOLFIRI + Bevacizumab: Frequency of Adverse Events (AEs) | 37 of 37 | 38 of 38 | 75 | NCT05983367 | Trial comparisons |
| Ompenaclid + FOLFIRI + Bevacizumab vs Placebo + FOLFIRI + Bevacizumab: serious adverse events | 12 of 37 | 9 of 38 | 75 | NCT05983367 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0024331/comparisons